Explore
Validate
Learn
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [2]
- Comments [0]
- Validations
- Western blot [1]
- Other assay [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA1-4130 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- CUG-BP2 Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Synthetic peptide
- Description
- PA1-4130 detects ETR-3 in human and mouse samples.
- Concentration
- 1 mg/mL
Submitted references Suppression of miR-106a-5p expression inhibits tumorigenesis via increasing CELF-2 expression in spinal cord glioma.
Diversity and conservation of CELF1 and CELF2 RNA and protein expression patterns during embryonic development.
Xu H, Wang F, Wang L
Oncology letters 2021 Aug;22(2):627
Oncology letters 2021 Aug;22(2):627
Diversity and conservation of CELF1 and CELF2 RNA and protein expression patterns during embryonic development.
Blech-Hermoni Y, Stillwagon SJ, Ladd AN
Developmental dynamics : an official publication of the American Association of Anatomists 2013 Jun;242(6):767-77
Developmental dynamics : an official publication of the American Association of Anatomists 2013 Jun;242(6):767-77
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot detection of ETR-3 from heart lysate using Product # PA1-4130.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Expression of CELF1 and CELF2 proteins in a panel of chicken embryonic tissues. CELF1 and CELF2 protein expression in heart (he), liver (li), hindbrain (hb), and eye (ey) from stages 26 and 35 was assessed by western blot. Ponceau S staining was used to show total protein integrity and loading. Bars by western blots indicate the relative position of the 50/52-kDa ladder marker for that blot. Blots shown are representative of three independent experiments.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 3. miR-106a-5p promotes tumor progression by inhibiting CELF-2 expression in 0213SCG cells. (A) Predicted binding site of miR-106a-5p in the CELF-2 3'-UTR region using TargetScan. (B) Reverse transcription-quantitative PCR assays showed that the miR-106a-5p inhibitor significantly increased the expression levels of CELF-2 in 0213SCG cells. (C) Western blot results showed the CELF-2 protein expression in 0213SCG cells treated with PBS, inCON and miR-106a-5p inhibitor. (D) Quantitative analysis results revealed that CELF-2 protein expression was significantly increased by the miR-106a-5p inhibitor. Data are expressed as the mean +- SEM. *P
